Abstract
Background & Objective: Cariprazine is a piprazine derivative approved by the FDA in 2015 for the treatment of schizophrenia and bipolar manic or mixed episodes in adults. High affinity for D3 dopamine receptors and observed actions on 5HT1A, 5HT2A and alpha 1B receptors differentiate it pharmacologically from other antipsychotics. This review is a comprehensive and thorough summary of the most important findings on cariprazine use in bipolar mania and depression. Pharmacokinetics, pharmacogenetics, tolerability and safety adverse effects are discussed in this paper.
Results & Conclusion: Moreover, the results from pivotal clinical trials are presented. Cariprazine represents an additional option for clinicians to treat patients with bipolar disorder. It shows a unique pharmacological profile and has demonstrated in randomized clinical trials efficacy and general tolerability compared to placebo in bipolar mania and seem to be a promising therapeutic option for bipolar depression.
Keywords: Cariprazine, D3 receptor, bipolar disorder, bipolar mania, bipolar depression, psychiatric disease.
Graphical Abstract
CNS & Neurological Disorders - Drug Targets
Title:Cariprazine in Bipolar Depression and Mania: State of the Art
Volume: 17 Issue: 10
Author(s): Marianna Mazza*, Giuseppe Marano, Gianandrea Traversi, Valentina Carocci, Benedetta Romano and Luigi Janiri
Affiliation:
- Institute of Psychiatry and Psychology, Department of Geriatrics, Neuroscience and Orthopedics, Fondazione Policlinico Universitario A. Gemelli IRCSS, Universita Cattolica del Sacro Cuore, Rome,Italy
Keywords: Cariprazine, D3 receptor, bipolar disorder, bipolar mania, bipolar depression, psychiatric disease.
Abstract: Background & Objective: Cariprazine is a piprazine derivative approved by the FDA in 2015 for the treatment of schizophrenia and bipolar manic or mixed episodes in adults. High affinity for D3 dopamine receptors and observed actions on 5HT1A, 5HT2A and alpha 1B receptors differentiate it pharmacologically from other antipsychotics. This review is a comprehensive and thorough summary of the most important findings on cariprazine use in bipolar mania and depression. Pharmacokinetics, pharmacogenetics, tolerability and safety adverse effects are discussed in this paper.
Results & Conclusion: Moreover, the results from pivotal clinical trials are presented. Cariprazine represents an additional option for clinicians to treat patients with bipolar disorder. It shows a unique pharmacological profile and has demonstrated in randomized clinical trials efficacy and general tolerability compared to placebo in bipolar mania and seem to be a promising therapeutic option for bipolar depression.
Export Options
About this article
Cite this article as:
Mazza Marianna *, Marano Giuseppe , Traversi Gianandrea , Carocci Valentina, Romano Benedetta and Janiri Luigi , Cariprazine in Bipolar Depression and Mania: State of the Art, CNS & Neurological Disorders - Drug Targets 2018; 17 (10) . https://dx.doi.org/10.2174/1871527317666180828120256
DOI https://dx.doi.org/10.2174/1871527317666180828120256 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Holocaust, War Trauma and Reconciliation: Commentary on the Special Section
Adolescent Psychiatry Increasing Expression of Heme Oxygenase-1 by Proteasome Inhibition Protects Astrocytes from Heme-mediated Oxidative Injury
Current Neurovascular Research mTOR Inhibitors in Tuberous Sclerosis Complex
Current Neuropharmacology Huntingtons Disease: New Frontiers for Molecular and Cell Therapy
Current Drug Targets Major Mental Disorders and Violence: A Critical Update
Current Psychiatry Reviews Structure-based Vaccine Design in HIV: Blind Men and the Elephant?
Current Pharmaceutical Design Oligonucleotides and G-quadruplex Stabilizers: Targeting Telomeres and Telomerase in Cancer Therapy
Current Pharmaceutical Design Recent Progress in Metal-Mediated Trifluoroethylation
Current Organic Chemistry Influence of Polymorphic N-Acetyltransferases on Non-Malignant Spontaneous Disorders and on Response to Drugs
Current Drug Metabolism Structural Alterations of the Retinal Microcirculation in the “Prehypertensive” High- Normal Blood Pressure State
Current Pharmaceutical Design Hepatocellular Carcinoma in Alcoholic Liver Disease: Current Management and Recent Advances
Reviews on Recent Clinical Trials New Trends in the Development of Oral Antidiabetic Drugs
Current Medicinal Chemistry Recent Advances in the Development of Nonpeptide Somatostatin Receptor Ligands
Mini-Reviews in Medicinal Chemistry Trough Plasma Concentrations of Mifepristone Correlate with Psychotic Symptom Reductions: A Review of Three Randomized Clinical Trials
Current Psychiatry Reviews Editorial (Thematic Issue : Gut Permeability and the Microbiome: Emerging Roles in CNS Function in Health and Disease)
Current Pharmaceutical Design Computational Models for Central Nervous System Penetration
Current Computer-Aided Drug Design Unusual DNA Conformations: Implications for Telomeres
Current Medicinal Chemistry - Anti-Cancer Agents 9.4T Magnetic Resonance Imaging of the Mouse Circle of Willis Enables Serial Characterization of Flow-Induced Vascular Remodeling by Computational Fluid Dynamics
Current Neurovascular Research Analytical Methods for the Measurement of Catechol-O-Methyltransferase Activity in Animal Tissues
Current Biotechnology Protein-protein Interactions: Network Analysis and Applications in Drug Discovery
Current Pharmaceutical Design